Exelixis (EXEL) return on equity (ROE)

Return on equity · fiscal 2025
36.2%

Exelixis (EXEL) earned a return on equity of 36.2% in fiscal 2025 (the year ended December 31, 2025). That is 13.0 percentage points higher than the 23.2% of fiscal 2024. Figures as of 17 Nov 2026, 21:15 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on equity, fiscal 2025
36.2%
Change on fiscal 2024
+13.0 pts
Highest on record
83.5%fiscal 2011
Lowest on record
-1642.9%fiscal 2013
Fiscal years on record
142011–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Exelixis return on equity (ROE), in more detail

Across the 14 fiscal years on record (2011–2025), the highest was 83.5% in fiscal 2011 and the lowest -1642.9% in fiscal 2013. The fiscal 2025 figure is higher than in 77% of the 13 earlier fiscal years on record, whose median is 9.2%.

History · 14 fiscal years

Return on equity by fiscal year

Exelixis return on equity (ROE), year by year

Exelixis (EXEL) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
202536.2% 13.0 pts up
202423.2% 14.1 pts up
20239.2% 1.9 pts up
20227.3% 3.1 pts down
202110.5%—
20215.9% 13.1 pts down
202019.0%—
201853.6% 0.5 pts down
201754.1% 132.7 pts up
2016-78.6%—
2016-78.6%—
2013-1642.9% 1581.9 pts down
2012-61.0% 144.6 pts down
201183.5%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

Return on equity at health care companies of similar size

Return on equity of Exelixis and comparable companies
CompanyReturn on equityFiscal year
Medpace Holdings MEDP98.3%2025
Revvity RVTY3.3%2025
Exelixis EXEL36.2%2025
Charles River Laboratories International CRL-4.6%2025
Neurocrine Biosciences NBIX14.7%2025
Ascendis Pharma ASND-221.5%2022

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on EXEL

Exelixis, figure by figure

Exelixis (EXEL) overview: price, valuation and scorecardAll health care companies by market value

Exelixis return on equity (ROE): questions and answers

What is Exelixis's return on equity?

Exelixis (EXEL) earned a return on equity of 36.2% in fiscal 2025 (the year ended December 31, 2025). That is 13.0 percentage points higher than the 23.2% of fiscal 2024.

Is Exelixis's return on equity high or low compared with its own history?

The fiscal 2025 figure is higher than in 77% of the 13 earlier fiscal years on record, whose median is 9.2%.

What are the highest and lowest return on equity figures on record for Exelixis?

Across the 14 fiscal years on record (2011–2025), the highest was 83.5% in fiscal 2011 and the lowest -1642.9% in fiscal 2013.

How is Exelixis's return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Exelixis (EXEL) return on equity (ROE)”, data as of 17 November 2026. https://funkfolio.com/stock/EXEL/roe

Underlying data: the company's filings with the SEC and Yahoo Finance.